Caribou Biosciences Inc Asset Resilience Ratio
Caribou Biosciences Inc asset resilience ratio. Caribou Biosciences Inc (CRBU) has an Asset Resilience Ratio of 60.32% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Caribou Biosciences Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Caribou Biosciences Inc (2019–2025)
Asset resilience ratio of Caribou Biosciences Inc from 2019 to 2025. This chart shows how Caribou Biosciences Inc's Asset Resilience Ratio has changed over time. Read Caribou Biosciences Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Caribou Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see CRBU total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $86.12 Million | 60.32% |
| Total Liquid Assets | $86.12 Million | 60.32% |
Asset Resilience Insights
- Very High Liquidity: Caribou Biosciences Inc maintains exceptional liquid asset reserves at 60.32% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Caribou Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Caribou Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Ascendis Pharma AS
F:A71 |
Biotechnology | 0.00% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.58% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Disc Medicine Inc.
NASDAQ:IRON |
Biotechnology | 84.22% |
|
Alpha Tau Medical Ltd
NASDAQ:DRTS |
Biotechnology | 65.79% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
Caribou Biosciences Inc Asset Resilience Ratio by Year (2019–2025)
Caribou Biosciences Inc asset resilience ratio by year from 2019 to 2025. The table below shows the annual Asset Resilience Ratio data for Caribou Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 72.41% | $126.98 Million | $175.37 Million | +10.73pp |
| 2024-12-31 | 61.68% | $193.24 Million | $313.31 Million | -2.57pp |
| 2023-12-31 | 64.24% | $277.67 Million | $432.21 Million | +13.59pp |
| 2022-12-31 | 50.65% | $189.32 Million | $373.76 Million | +20.04pp |
| 2021-12-31 | 30.61% | $135.41 Million | $442.36 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $36.05 Million | -- |
| 2019-12-31 | 13.56% | $8.40 Million | $61.93 Million | -- |
About Caribou Biosciences Inc
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD… Read more